Hepatitis B Articles (HBV)
Back
	Hepatitis B (HBV)       Hep B Articles...   Eurpopean Association for the Study of the Liver (EASL) March 30th - April 3rd 2011 Berlin, Germany   The 21st Conference of the Asian Pacific Association for the Study of the Liver APASL Feb 17-20, 2011 Bangkok, Thailand   61th Annual Meeting of the American (AASLD) Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010   Hepatitis B (HBV) at AASLD   Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 μg: NEPTUNE study - (11/08/10)   EASL: NEPTUNE STUDY: ON-TREATMENT HBsAg LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBeAg-POSITIVE PATIENTS - (04/13/11)   Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment - (11/29/10)   No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (11/08/10)   AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)   AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)   Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027 - (11/21/10)   Long-term Entecavir Treatment for Up to 5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results From ETV-022 and -901 - (11/21/10)   Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B4. - (11/21/10)   Safety Findings From S-Collate, A Large, Multinational, Non-Interventional Cohort Study Of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40kd] - (11/21/10)   Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience - (11/21/10)   Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40KD] in genotype D patients with HBeAg-negative chronic hepatitis B - (11/21/10)   Changes In HBsAg Levels Among Patients With Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40kd] Enrolled In The S-Collate Cohort Study - (11/21/10)   Changes In HBeAg Levels Among Patients With HBeAg-Positive Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40KD] Enrolled In The S-Collate Cohort Study - (11/21/10)   Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/15/10)           View Older Articles   Back to Top   www.natap.org